Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on May 4, 2026, covering events occurring on May 1, 2026. The Company is a clinical-stage biopharmaceutical firm focused on advancing PAS-004 for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform and cutaneous neurofibromas.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and compensation matters.
Material Changes
- Executive Appointment: Kartik Krishnan, M.D., Ph.D., was appointed Chief Medical Officer (CMO), effective May 1, 2026. Dr. Krishnan will oversee clinical development and medical strategy.
- Compensation Structure: Dr. Krishnan's employment agreement includes a base salary of $500,000 and an annual discretionary bonus of up to 40% of base salary.
- Equity Grants: The Board approved stock option awards for executive officers, employees, and non-employee directors with an exercise price of $0.841 per share (closing price on May 1, 2026).
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking revenue projections, or specific risk factor updates beyond standard disclosures regarding the terms of the employment agreement and equity plans. The appointment is intended to strengthen the Company's clinical development capabilities for its lead asset, PAS-004.
Investor Verification Checklist
- Verify the vesting schedule for the new CMO's stock options (33% at one year, remainder quarterly over two years).
- Confirm the total number of shares granted to executives and employees (approx. 5.25 million shares total across all recipients).
- Review the full Executive Employment Agreement (Exhibit 10.1) for specific severance terms and change-in-control provisions.
- Monitor future filings for clinical trial updates related to PAS-004 under Dr. Krishnan's leadership.